Cargando…

A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study

BACKGROUND: Financial toxicity (FT) has a negative impact on the quality of life and survival of patients with cancer. The comprehensive score for FT (COST) questionnaire is a tool to measure FT which has already been validated in patients with cancer in the United States. However, the feasibility a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Honda, Kazunori, Gyawali, Bishal, Ando, Masashi, Sugiyama, Keiji, Mitani, Seiichiro, Masuishi, Toshiki, Narita, Yukiya, Taniguchi, Hiroya, Kadowaki, Shigenori, Ura, Takashi, Muro, Kei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2018
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057653/ https://www.ncbi.nlm.nih.gov/pubmed/30079109 http://dx.doi.org/10.3332/ecancer.2018.847

Ejemplares similares

Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer
por: Honda, Kazunori, et al.
Publicado: (2019)

Successful Treatment of Cardiac Angiosarcoma Associated with Disseminated Intravascular Coagulation with Nab-Paclitaxel: A Case Report and Review of the Literature
por: Honda, Kazunori, et al.
Publicado: (2017)

The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation
por: Mitani, Seiichiro, et al.
Publicado: (2019)

Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: A case series and review of the literature
por: Mitani, Seiichiro, et al.
Publicado: (2017)

Clinical outcomes of patients diagnosed with cancer of unknown primary or malignancy of undefined primary origin who were referred to a regional cancer center
por: Ando, Masashi, et al.
Publicado: (2023)

Combination of Oxaliplatin and 5-Fluorouracil/Leucovorin for Advanced Esophageal Squamous Cell Carcinoma Refractory or Intolerant to Standard Therapies
por: Mitani, Seiichiro, et al.
Publicado: (2019)

A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer
por: Hashimoto, Naoya, et al.
Publicado: (2018)

Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study
por: Taniguchi, Hiroya, et al.
Publicado: (2023)

Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer
por: Taniguchi, Hiroya, et al.
Publicado: (2021)

Pseudocirrhosis in Gastric Cancer with Diffuse Liver Metastases after a Dramatic Response to Chemotherapy
por: Mitani, Seiichiro, et al.
Publicado: (2016)

Risk of second primary malignancies after definitive treatment for esophageal cancer: A competing risk analysis
por: Mitani, Seiichiro, et al.
Publicado: (2019)

A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer
por: Yamaguchi, Kazuhisa, et al.
Publicado: (2015)

First experience of a fully decentralized clinical trial: The dawn of a new era in oncology
por: Taniguchi, Hiroya, et al.
Publicado: (2023)

Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer
por: Masuishi, Toshiki, et al.
Publicado: (2019)

Updated Immunotherapy for Gastric Cancer
por: Narita, Yukiya, et al.
Publicado: (2023)

Low-value practices in oncology contributing to financial toxicity
por: Gyawali, Bishal
Publicado: (2017)

A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma
por: Ooki, Akira, et al.
Publicado: (2022)

Dramatic Response in a Patient with Metastatic Gastric Cancer Using Trifluridine/Tipiracil after Rapid Disease Progression while on Nivolumab
por: Nozawa, Kazuki, et al.
Publicado: (2020)

Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions
por: Desai, Aakash, et al.
Publicado: (2020)

Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study
por: Yoshikawa, Akie Kimura, et al.
Publicado: (2022)

Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer
por: Kawai, Sadayuki, et al.
Publicado: (2020)

Marked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability‐high gastric cancer with insufficient oral intake
por: Ogata, Takatsugu, et al.
Publicado: (2020)

Durable Response of Human Epidermal Growth Factor Receptor-2-Positive Gastric Adenosquamous Carcinoma to Trastuzumab-Based Chemotherapy
por: Kadowaki, Shigenori, et al.
Publicado: (2014)

Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study
por: Kotani, Daisuke, et al.
Publicado: (2021)

Job stress and work from home during the COVID-19 pandemic among Japanese workers: a prospective cohort study
por: Ikegami, Kazunori, et al.
Publicado: (2023)

Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients11
por: Taniguchi, Hiroya, et al.
Publicado: (2015)

Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma
por: Kadowaki, Shigenori, et al.
Publicado: (2013)

Workplace infection prevention control measures and work engagement during the COVID‐19 pandemic among Japanese workers: A prospective cohort study
por: Ikegami, Kazunori, et al.
Publicado: (2022)

A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients
por: Nishina, Tomohiro, et al.
Publicado: (2013)

Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition
por: Yamazaki, Kentaro, et al.
Publicado: (2018)

Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial
por: Muro, Kei, et al.
Publicado: (2019)

Gram-stain-based antimicrobial selection reduces cost and overuse compared with Japanese guidelines
por: Taniguchi, Tomohiro, et al.
Publicado: (2015)

Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study
por: Kato, Ken, et al.
Publicado: (2018)

Effective Treatment of Intestinal Behçet's Disease with Long-Term, Low-Dose Clarithromycin
por: Hakozaki, Yukiya, et al.
Publicado: (2013)

Cancer drugs in LMICs: cheap but unaffordable
por: Gyawali, Bishal
Publicado: (2017)

The OlympiAD trial: who won the gold?
por: Gyawali, Bishal
Publicado: (2017)

Me, Too
por: Gyawali, Bishal
Publicado: (2016)

Letter to Editor-response: placebo response rates
por: Gyawali, Bishal
Publicado: (2023)

Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features
por: Watari, Jiro, et al.
Publicado: (2019)

Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer
por: Kato, K., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_djspvq7p03vb21smo1b7eitr54